MedTrace Logo

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

NCT00696345 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2008-06-17

No results posted yet for this study

Summary

Epigenomics is developing a colon cancer screening assay based on differential methylation of specific CpG sites for the detection of early stage disease. A genome-wide methylation analysis and oligonucleotide array study using DNA from various stages of colon cancer and normal tissue have been completed to obtain candidate CpG markers. Based on results obtained in the above studies, Epigenomics has moved to the final stages of feasibility with a specific, highly sensitive real-time marker assay that is able to detect colon cancer DNA in blood plasma.

Conditions

Sponsors & Collaborators

  • Epigenomics, Inc

    lead INDUSTRY

Principal Investigators

  • Catherine Lofton-Day, PhD · Epigenomics, Inc

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-10-31
Completion
2007-02-28

Countries

  • Germany
  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00696345 on ClinicalTrials.gov